

AD _____

GRANT NUMBER: DAMD17-94-J-4498

TITLE: The Role of Heparin-Binding EGF-Like Growth Factor in Breast Cancer

PRINCIPAL INVESTIGATOR: David S. Salomon, Ph.D.

CONTRACTING ORGANIZATION: National Institutes of Health
Bethesda, Maryland 20892

REPORT DATE: October 1996

TYPE OF REPORT: Annual

PREPARED FOR: Commander
U.S. Army Medical Research and Materiel Command
Fort Detrick, Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

**Personally Identifiable
Information Redacted**

DTIC QUALITY INSPECTED 1

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE October 1996	3. REPORT TYPE AND DATES COVERED Annual (30 Sep 95 - 29 Sep 96)	
4. TITLE AND SUBTITLE The Role of Heparin-Binding EGF-Like Growth Factor in Breast Cancer			5. FUNDING NUMBERS DAMD17-94-J-4498	
6. AUTHOR(S) David S. Salomon, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) National Institutes of Health Bethesda, Maryland 20892			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) Commander U.S. Army Medical Research and Materiel Command Fort Detrick, Frederick, Maryland 21702-5012			10. SPONSORING/MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200) Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a member of the EGF family which binds to and activates the EGF receptor. Its role in breast cancer, however, is unclear. We have studied the regulation of HB-EGF expression in nontransformed and transformed mammary epithelial cells. HB-EGF is induced by 12-o-tetradecanoylphorbol-13-acetate (TPA) in most of the cell lines analyzed. In contrast with transforming growth factor alpha or amphiregulin, HB-EGF is not induced by estrogen or progesterone in any of the estrogen responsive, estrogen receptor positive breast cancer cell lines examined. HB-EGF mRNA levels are induced by EGF-related peptides in the spontaneously immortalized mammary epithelial cell line MCF-10A. EGF was the most potent activator. AR mRNA levels are also induced by EGF-related peptides acting through the EGF receptor. Additionally, we have analyzed the ability of HB-EGF to phosphorylate erbB receptors compared to other EGF-related peptides. HB-EGF and betacellulin were able to induce autophosphorylation of erbB-3 in MCF-10A cells. HB-EGF was more potent than EGF or amphiregulin on the induction of colony formation of some breast cancer cell lines analyzed.				
14. SUBJECT TERMS Breast Cancer			15. NUMBER OF PAGES 51	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

19970314 106

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

_____ Where copyrighted material is quoted, permission has been obtained to use such material.

_____ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

_____ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

_____ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

_____ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

PSS In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

PSS In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

PSS In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

David A. Suen 10/29/96
PI - Signature Date

TABLE OF CONTENTS

	page
Introduction.....	5
Experimental methods.....	6
Results.....	9
Discussion.....	11
Conclusion.....	13
Figure legends.....	14
References.....	17

INTRODUCTION

Heparin-binding epidermal growth factor (HB-EGF) is a recently described member of the EGF family which binds to the EGF receptor. It was originally isolated from conditioned media of the human monocyte-like U-937 cells that were induced with 12-*O*-tetradecanoylphorbol-13-acetate (TPA)) (Higashiyama *et al.*, 1991). Little is known about the role of HB-EGF in breast cancer, which is the scope of this project. Others members of the EGF family such as transforming growth factor alpha (TGF- α) and amphiregulin (AR) are known to be induced by TPA in breast cancer cells (Bjorge *et al.*, 1989; Plowman *et al.*, 1990) and also by steroid hormones such as 17- β -estradiol (E₂) (Bates *et al.*, 1988; Martínez-Lacaci *et al.*, 1995). We wanted to analyze whether HB-EGF can be induced by these agents in nontransformed and transformed human mammary epithelial cells. HB-EGF has been shown to be induced by estrogen and progesterone in the uterus (Wang *et al.*, 1994; Zhang *et al.*, 1994).

One important characteristic of HB-EGF is that it binds to heparin (Besner *et al.*, 1992), like AR or betacellulin (BTC). We suspect that in this respect, it might have a different role than other EGF-related peptides which lack the ability to bind to heparin.

Other EGF-related peptides can also be induced by EGF (Barnard *et al.*, 1994). We wanted to study the auto and cross-induction of HB-EGF with all the EGF-related peptides to determine whether there was any differential mechanism of induction between these peptides and/or between nontransformed and transformed mammary epithelial cells. Additionally, we wanted to determine whether HB-EGF was able to stimulate activation of other EGF receptor related molecules, such as *erbB-2*, *erbB-3* and *erbB-4* and its potency as a growth factor in anchorage-dependent and anchorage-independent conditions.

It has been recently shown that HB-EGF is an early responsive gene that can be activated by the ras/raf signaling pathway (McCarthy *et al.*, 1995). We wanted to test this hypothesis in human transformed mammary epithelial cells that have been transfected with the ras oncogene (Basolo *et al.*, 1991). We wanted to determine whether mitogen-activated protein (MAP) kinase was involved in the pathway of induction of HB-EGF. Additionally, EGF and TGF- α have been shown to activate phospholipase A₂ (PLA₂) (Schalkwijk *et al.*, 1995; Kast *et al.*, 1993) which in turn can be activated by MAP kinase (Lin *et al.*, 1993). We wanted to determine whether there is a cross-talk between these two pathways upon stimulation of HB-EGF.

EXPERIMENTAL METHODS

Reagents: Human mammary epithelial cells were obtained from the following sources: Dr. Samuel Brooks, Michigan Cancer Foundation, Detroit, MI, the American Type Culture Collection (ATCC), Rockville, MD, Dr. Stephen Ethier, University of Michigan Breast Cancer/Tissue Bank and Data Base, Ann Harbor, MI and Dr. Marc Lippman, Lombardi Cancer Center, Georgetown University, Washington, D.C. The BS-HBE clone was constructed by subcloning a 402-bp restriction fragment of the HB-EGF cDNA into the Eco RI-Kpn I site of the pBC KS⁻ polylinker region. The pGEM-AR and p36B4 clones have already been described (Martínez-Lacaci *et al.*, 1995; Saceda *et al.*, 1988). The pUC (7-1) clone containing a 1.1 Kb HB-EGF cDNA fragment was obtained from Dr. Judith Abraham, Scios Nova Inc., Mountain View, CA. Mouse monoclonal antibodies 308.2 and 1001.1 against human HB-EGF were also obtained from Dr. Judith Abraham. An anti-goat neutralizing antibody against HB-EGF was purchased from R&D Systems, Minneapolis, MN. The rabbit polyclonal antibodies H₂ and H₆ raised against HB-EGF were obtained from Dr. Shigeki Higashiyama, Osaka University Medical School, Osaka, Japan. The monoclonal antibody 4 against *erbB*-3 was purchased from Neomarkers, Fremont, CA. The monoclonal antibody L₂ against EGF and the anti-phosphotyrosine monoclonal antibody PY20 were purchased from Transduction Laboratories, Lexington, KY. A rabbit polyclonal antibody against ERK-1 was purchased from Santa Cruz Biotechnology Inc., Santa Cruz, CA and a monoclonal antibody against ERK-2 was purchased from Upstate Biotechnology Inc., Lake Placid, NY.

Cell culture: Nontransformed and transformed human mammary epithelial cells were grown in the appropriate media according to ATCC specifications. Depending on the experiment, media was replaced to phenol red-free Improved Minimal Essential Medium (IMEM) containing 5% charcoal-treated calf serum (CCS) or media without EGF and cells were maintained under these conditions for 3-4 days. Additionally, media was replaced to basic media without serum for 24 hr and cells were treated with different peptides, steroids or drugs for appropriate times.

Isolation of RNA: Total cellular RNA was isolated from nontransformed and transformed human mammary epithelial cells using the Perfect RNA total RNA isolation kit (5 Prime-3 Prime, Inc, Boulder, CO) and stored at -70°C. RNA was dissolved in 70% ethanol and the optical density at 260 and 280 nm was determined.

RNase protection assay: ^{32}P -labeled antisense riboprobes were *in vitro* synthesized from BS-HBE, pGEM-AR and p36B4 using T3, SP6 and T7 polymerases, respectively. Subsequently, 60- μg aliquots of total RNA isolated from nontransformed and transformed human breast epithelial cells were hybridized for 12-16 hr at 50°C, and treated with RNase A for 30 min at 25°C. The protected fragments were electrophoresed on a 6% polyacrylamide gel, which was subsequently dried and exposed to autoradiography.

Western blot analysis: Human breast cancer cells were lysed using lysis buffer containing 20 mM Tris pH 7.5, 100 mM NaCl, 1% Nonidet-P40, 0.5% deoxycholate, 5 mM MgCl_2 and protease inhibitors: leupeptin (5 $\mu\text{g}/\text{ml}$), aprotinin (20 $\mu\text{g}/\text{ml}$) and phenylmethylsulfonyl fluoride (35.8 $\mu\text{g}/\text{ml}$) and incubated for 15 min at 4°C. Alternatively, conditioned media were collected and concentrated using Centricon concentrators. Protein concentration of the samples was determined and 80 μg were subjected to 4-20% Tris-Glycine SDS-PAGE, transferred to PVDF membranes, blocked with Tris-buffered saline (TBS) containing 0.05% Tween-20 (TBST) and 3% bovine serum albumin (BSA) or 5% non-fat dry milk for 3-16 hr, incubated with antibodies against HB-EGF for 3-16 hr, washed, incubated for 1 hr with a secondary antibody linked to horseradish peroxidase, washed, incubated with enhanced chemiluminescence (ECL) reagents for 1 min and exposed to autoradiography.

c-erbB receptor autophosphorylation assay: Nontransformed and breast cancer human mammary epithelial cells were grown in 100-mm dishes. When they were 50% confluent, medium was replaced with complete medium except EGF for 3-4 days or with IMEM containing 5% CCS and subsequently, cells were serum-starved for 24 hr. Cells were treated with EGF-related peptides for 10 min, lysed with lysis buffer containing 1% Triton X-100, 10 mM Tris, pH 7.6, 5mM EDTA, 50 mM NaCl, 30 mM sodium pyrophosphate, 50 mM sodium fluoride and 1mM sodium orthovanadate and protease inhibitors for 15 min at 4°C. Cells were scraped, centrifuged at 14,000 x g for 15 min at 4°C and supernatant was transferred to a clean tube. Subsequently, protein concentration of the samples was determined and 300 μg of protein were incubated with 1 μg of antibodies against EGF receptor, c-erbB-3 or c-erbB-4 and rotated end over end for 2 hr. Subsequently, samples were incubated with protein G Sepharose beads and rotated for 1 hr at 4°C. Beads were washed three times with lysis buffer, dried, resuspended in lysis buffer. Proteins were eluted by boiling the beads for 7 min and by centrifugation at 14,000 x g for 15 min. Samples were subjected to 8% SDS-PAGE, transferred to a PVDF membrane, blocked with 3% BSA-TBST and incubated with anti-phosphotyrosine

antibody (PY20) for 3 hr. Membranes were washed, incubated with a secondary antibody linked to horseradish-peroxidase, washed, incubated with ECL reagents for 1 min and exposed to autoradiography.

MAP kinase assay: MCF-10A nontransformed and transformed cells were lysed as described above for Western blot analysis, protein concentration was determined and 80 µg were subjected to 4-20% SDS-PAGE. Subsequently, samples were transferred to a PVDF membrane, blocked with 3% BSA-TBST, incubated with an anti ERK 2 antibody for 3 hr, washed, incubated with a secondary antibody coupled to alkaline phosphatase for 1 hr, washed and incubated with 5-bromo-4-chloro-3-indolyl-phosphate and nitroblue tetrazolium until color appear.

Myelin basic protein (MBP) assay: MCF-10A nontransformed and transformed cells were lysed in a buffer containing 1% Nonidet-P40, 0.5 % deoxycholate, 20 mM Tris, pH 7.5, 150 mM NaCl, 1 mM sodium orthovanadate and proteinase inhibitors as described above and incubated for 15 min at 4°C. Subsequently, protein concentration was determined and 100 µg were diluted up to 300 µl with lysis buffer, incubated with 1 µg of an antibody against ERK-1 and rotated end over end for 2 hr at 4°C. Protein G Sepharose beads were added to the mixture and rotated for 1 hr at 4°C. Subsequently, beads were washed, resuspended in kinase buffer containing 30 mM Hepes, pH 7.4, 10 mM MgCl₂, 10 mM MnCl₂ and 1mM DTT, 5 µg of MBP and 5 µCi of ³³p-labeled ATP were added and beads were incubated for 30 min at 30°C. Sample buffer was added and proteins were eluted from beads by boiling the samples for 7 min, electrophoresed on a 4-20 % SDS-PAGE and exposed to autoradiography.

Anchorage-independent growth assays: Human breast cancer cells were suspended in 0.36% agar supplemented with phenol red-free IMEM containing 5% CCS and 10 ng/ml of the appropriate EGF-related peptides (10 ng/ml) or 1 nM E₂ and were seeded over a 0.8% agar base layer. After 14 days, cells were stained with nitroblue tetrazolium and colonies larger than 50 µm were counted on an Artek Colony Counter.

RESULTS

Expression levels of HB-EGF in human breast cancer cell lines: HB-EGF mRNA levels were analyzed by RNase protection assays in various nontransformed and transformed human mammary epithelial cells. In general, the basal levels of expression were low, unless cells were induced with 100 nM TPA, with the exception of the human breast cancer cell line MDA-MB-453. The estrogen-independent ER negative MDA-MB-231 human breast cancer cell line showed the highest level of HB-EGF mRNA, being induced with TPA within 1 hr (Fig. 1). The estrogen-responsive, estrogen receptor (ER) positive human breast cancer cell line MCF-7 was treated with 100 nM TPA or with 1 nM E₂ at different times (Fig. 2). Additionally, MCF-7 cells were treated with TPA, E₂, the pure antiestrogen 10⁻⁷ M ICI 182 780, 1nM 6 α -methyl-17 α -hydroxyprogesterone (MPA) or combination of these drugs for 24 hr (Fig. 3). The estrogen-responsive, ER positive human breast cancer cell line T-47D cell was treated with TPA, E₂, ICI 182 780, MPA or combination of these drugs for 6 and 24 hr (Fig. 4). In contrast with TGF- α and AR the levels of HB-EGF mRNA were not induced with E₂ in any of the estrogen-responsive, ER positive breast cancer cell line tested. Progesterone was also unable to induce HB-EGF mRNA levels in the breast cancer cell lines tested studied.

Effects of EGF-related peptides on HB-EGF mRNA levels: The spontaneously immortalized, nontransformed human mammary epithelial cell line, MCF-10A, was treated with different EGF-related peptides to analyze the effect they had on the induction of HB-EGF mRNA levels. HB-EGF mRNA was induced with the following peptides (10 ng/ml): EGF, TGF- α , AR, HB-EGF, BTC and biregulin (BIR) at 3 hr and at 24 hr (Fig. 5, 6 and 7). In contrast, heregulin (HRG- β 1), cripto-1 (CR-1) and the stromal-derived factors hepatocyte growth factor (HGF) and keratinocyte growth factor (KGF) did not have any effect at any of the time points analyzed. TPA was used as a positive control. HB-EGF was induced very rapidly with the EGF-related peptides. However, the induction of HB-EGF with EGF seemed to be more prolonged compared to the effect of the other peptides (Fig. 8).

Effects of EGF-related peptides on AR mRNA levels: MCF-10A cells were treated with several EGF-related peptides (EGF, TGF- α , AR, HB-EGF) at different times. AR mRNA levels were also induced with these factors and EGF seemed to be the most potent (Fig. 9).

Levels of HB-EGF in MCF-10A transformed cells: MCF-10A cells were transformed with *c-Ha-ras*. Levels of HB-EGF and AR mRNA were measured in different clones and compared to the parental cell line MCF-10A. Most of the clones showed enhanced levels of mRNA of both HB-EGF and AR (Fig. 10 and 11).

Levels of HB-EGF protein in human breast cancer cells: HB-EGF protein levels were measured in MDA-MB-231 cell lysates as well in their conditioned media by Western blot (data not shown). Unfortunately, the antibodies used were not able to detect any specific bands.

Phosphorylation of *erbB* receptors: Levels of phosphorylation of EGF receptor (EGFR), *erbB-3* and *erbB-4* were measured in MCF-10A, T-47D and MDA-MB-453 cells upon stimulation with different EGF-related peptides for 10 min. EGFR autophosphorylation was induced with EGF, HB-EGF and BTC in MCF-10 A cells (Fig. 12 Panel A). The AR preparation used in this particular experiment was not very active. HB-EGF and BTC were able to stimulate phosphorylation of *erbB-3* in MCF-10A cells, suggesting that a different signaling pathway may operate upon induction of these cells with HB-EGF or BTC (Fig. 12 Panel B).

Autophosphorylation of EGFR in MCF-10 ras clones: Levels of phosphorylation of EGFR were measured in MCF-10 ras clones. However, the levels of EGFR phosphorylation were almost the same in all the clones (data not shown).

Activation of MAP kinase in MCF-10 A clones: Levels of MAP kinase activity were measured in MCF-10 ras clones using two different approaches: MAP kinase assay and MBP assay (data not shown). However, this technique needs to be improved.

Effects of HB-EGF on anchorage independent growth of human breast cancer cells: The ability of HB-EGF to induce colony formation of the estrogen-responsive, ER positive ZR-75 and T-47D cells was measured and compared to the ability of E₂ and other EGF-related peptides (EGF and AR) to induce colony formation. HB-EGF was equipotent to E₂ (data not shown).

DISCUSSION

In this project the role of HB-EGF in breast cancer is been studied. In relation to the Statement of Work outlined in the proposal the following tasks have been attempted:

Task 1: *To analyze the HB-EGF mRNA and proteins levels in normal, benign and malignant breast tissues and in nontransformed and malignant human mammary epithelial cells.* The basal levels of HB-EGF mRNA have been analyzed in several transformed and nontransformed human mammary epithelial cells. MCF-10 A cells show very low levels of HB-EGF or AR mRNA when cells where deprived of EGF for 3-4 days followed by serum-starvation for 24 hr. In contrast, MCF-10A ras clones showed higher basal levels of both HB-EGF and AR under the same conditions (Fig 10 and 11). The SUM 102 PT cells also contain high levels of HB-EGF mRNA (data not shown). Most of the human breast cancer cell lines analyzed showed low levels of HB-EGF mRNA. MDA-MB-231 cells have higher basal levels of HB-EGF mRNA (Fig. 1) and MDA-MB-453 cells were negative for HB-EGF expression (data not shown). The levels of HB-EGF protein are under current study. We had some problems with the antibodies utilized for Western blot analysis, since they did not seem to work in a Western blot format. Conditioned media is being collected from MDA-MB-231 cells which express high levels of HB-EGF mRNA (Fig. 1) and protein (Raab et al., 1994) and we are going to run the conditioned media through a heparin column and either perform radioimmunoprecipitations after metabolically labeling cells with ^{35}S -methionine and ^{35}S -cysteine or perform Western blot using the enriched material. Additionally, a panel of breast tumor specimens and the adjacent non-involved tissue is being analyzed for HB-EGF expression by RT-PCR.

Task 2: *To measure the HB-EGF mRNA and protein levels in nontransformed and malignant human mammary epithelial cells after treatment with steroid hormones, differentiating agents and growth modulators.* HB-EGF was not induced by either estrogen or progesterone in any of the estrogen responsive, ER positive breast cancer cells analyzed (Fig. 2, 3 and 4). However, TPA was able to induce HB-EGF mRNA levels in all the cell lines analyzed with the exception of MDA-MB-453 cells. Induction of HB-EGF was analyzed in MCF-10A cells with different EGF-related peptides. Our preliminary data showed a differential effect of these peptides on induction, with EGF being the most potent activator after long periods of time (Fig. 6 and 8). TPA was also able to induce the levels of HB-EGF mRNA in these cells. We want to study the mechanism of induction with these factors and to determine whether there is a cross-talk between EGF and TPA. We will attempt to do this by using inhibitors of the EGF receptor (neutralizing antibodies, tyrphostins, etc) and protein kinase C inhibitors (Bryostatin and H-7). We believe that

heterodimer formation between EGFR and any of the other *erbB*-related receptors may be occurring (Pinkas-Kramarski *et al.*, 1996). We plan to use antibodies against these receptors to determine whether the HB-EGF induction can be blocked. Additionally, we want to study the signaling pathway and to test whether MAP kinase, PI-3 kinase or PLA₂ are involved in the pathway of HB-EGF induction of expression. In order to do that, we have analyzed the levels of HB-EGF mRNA in MCF-10A clones that have been transfected with a normal ras (N-ras) and a point mutated ras oncogene (Ha-ras). ras is known to activate MAP kinase. We are in the process of analyzing the MAP kinase activity levels in these clones under different conditions. Additionally, we are carrying out the same experiments to study the regulation of AR expression, which is a related member of the EGF family and we are planning to study the regulation of BTC as well using the same tools. The regulation of the expression of these three peptides may be different.

Task 3: *To characterize the mechanism of regulation of HB-EGF (transcriptional or post-transcriptional) after these treatments.* We are planning to carry out these studies once we have determined the most important findings in relation to the induction of HB-EGF expression.

Task 4: *To study the effect of HB-EGF on the ADG and AIG of nontransformed or transformed human mammary epithelial cells with activated oncogenes and of established human breast cancer cell lines to delineate how these effects might be modulated by such oncogenes.* We are in the process of accomplishing this task. Some preliminary studies showed that HB-EGF (10 ng/ml) as able to induce colony formation of the estrogen responsive, ER positive cell lines ZR-75 and T-47D at a greater extent than EGF or AR and it was as potent as E₂.

Task 5: *To determine whether HB-EGF can bind to and phosphorylate other receptors related to the EGF receptor (c-erbB2, c-erbB3, c-erbB4) in nontransformed and malignant human mammary epithelial cells.* We have measured the autophosphorylation of these receptors upon stimulation of HB-EGF and other EGF-related peptides in MCF-10A, T-47D and MDA-MB-453. HB-EGF and BTC were able to stimulate phosphorylation of *erbB*-3, as it has been reported (Beerli and Hynes, 1996). We are planning to continue these experiments using different conditions and cell lines in order to demonstrate whether HB-EGF is using a different signaling pathway than the other EGF-related peptides in this system.

CONCLUSIONS

In this project we have studied the regulation of HB-EGF expression in nontransformed and transformed mammary epithelial cells. In all the cells lines analyzed HB-EGF was induced by TPA except in the MDA-MB-453 cells which can be used as a negative control in future studies. In contrast with TGF- α or AR, HB-EGF mRNA levels were not induced by estrogen or progesterone. Additionally, HB-EGF mRNA levels were induced in the nontransformed MCF-10A cells with EGF-related peptides. The induction with EGF, however, seemed to be more sustained compared to the other peptides. HRG- β 1 or stromal-derived growth factors did not have any effect. AR mRNA levels were also induced with EGF-related peptides in a similar fashion. We want to determine the signaling pathway that is taking place and also to determine whether there is a cross-talk between the TPA and EGF pathways. HB-EGF has been shown to be induced by the ras/raf signaling pathway. We have analyzed HB-EGF and AR mRNA levels in MCF-10A cells transfected with a normal ras gene and a point mutated ras oncogene. In most of the ras clones, HB-EGF and AR mRNA levels were induced compared to the parental MCF-10A cells. We are in the process of analyzing the activity levels of MAP kinase in these clones and we are planning to determine the signaling pathway that is operative by using inhibitors. We have also studied whether HB-EGF was able to induce autophosphorylation of other erbB receptors such as *erbB-3* or *erbB-4* since heterodimer formation may be occurring. HB-EGF and BTC were able to stimulate phosphorylation of *erbB-3* in MCF-10A cells. The biological activity of HB-EGF in mammary epithelial cells is also being studied. HB-EGF was able to induce colony formation of some breast cancer cell lines and it was more potent than EGF or AR. Future studies will include all the studies that are necessary to accomplish the proposed tasks.

FIGURE LEGENDS

Fig. 1 Time course of TPA effects on HB-EGF mRNA levels. MDA-MB-231 cells were grown in IMEM supplemented with 5% fetal calf serum (FCS) and treated with TPA (100 nM) for 1, 3, 6, 24 and 48 hr. RNA was isolated and analyzed by RNase protection as described in Experimental Procedures. The HB-EGF and 36B4 (internal control) bands are indicated.

Fig. 2 Time course of TPA and E₂ effects on HB-EGF mRNA levels. MCF-7 cells were grown in IMEM supplemented with 5% FCS and after 2-4 days media were replaced with phenol red-free IMEM containing 5% CCS for 2-4 days. Cells were treated with TPA (100 nM) or with E₂ (1 nM) for 3, 6, 24 or 48 hr. Subsequently, RNA was isolated and analyzed by RNase protection. The HB-EGF and 36B4 bands are indicated.

Fig. 3 Effects of TPA, E₂, ICI and MPA on HB-EGF mRNA levels. MCF-7 cells were grown as described in the legend of Fig. 2 and treated with TPA (100 nM), E₂ (1 nM), ICI 182 780 (10^{-7} M), MPA (1 nM) or combinations of these drugs for 24 hr. RNA was isolated and processed for RNase protection analysis. The HB-EGF and 36B4 bands are indicated.

Fig. 4 Effects of TPA, E₂ and MPA on HB-EGF mRNA levels. T-47D cells were grown as described in the legend of Fig. 2 and treated with TPA, E₂ or MPA for 6 or 24 hr. RNA was isolated and analyzed by RNase protection. The HB-EGF and 36B4 bands are indicated.

Fig. 5 Effects of EGF-related peptides, KGF or HGF on HB-EGF mRNA levels. MCF-10A cells were grown in DMEM/HAMF12 supplemented with 5% horse serum, 10 U/ml penicillin-10 µg/ml streptomycin, 0.5 µg/ml hydrocortisone, 5 µg/ml insulin, 0.1 µg/ml cholera toxin and 20 ng/ml EGF. After 3-4 days, media were replaced to complete media except for EGF and maintained for 3-4 days. Subsequently, media were replaced to media without EGF, horse serum and insulin for 24 hr and cells were treated with different growth factors (10 ng/ml) for 3 hr. RNA was isolated and analyzed by RNase protection. The HB-EGF and 36B4 are indicated.

Fig. 6 Effects of EGF-related peptides, TPA, KGF or HGF on HB-EGF mRNA levels. MCF-10A cells were grown as described in the legend of Fig. 5 and

treated with different growth factors (10 ng/ml) or TPA (100 nM) for 24 hr. RNA was isolated and analyzed by RNase protection. The HB-EGF and 36B4 bands are indicated.

Fig. 7 Effects of EGF-related peptides, TPA, KGF or HGF on HB-EGF mRNA levels. Graphic representation of the experiment shown in Fig. 6. The HB-EGF and 36B4 bands were quantified by scanning densitometry. The HB-EGF mRNA bands were normalized with the corresponding 36B4 mRNA bands and represented as percentage of control.

Fig. 8 Time course of the effects of EGF-related peptides and TPA on HB-EGF mRNA levels. MCF-10A cells were grown as described in the legend of Fig. 5 and treated with different growth factors (10 ng/ml) or TPA (100 nM) for 1, 3, 6 or 24 hr. RNA was isolated and analyzed by RNase protection. The bands were quantified by scanning densitometry. The HB-EGF mRNA bands were normalized with the corresponding 36B4 mRNA bands and represented as percentage of control.

Fig. 9 Time course of the effects of EGF-related peptides on AR mRNA levels. MCF-10A cells were grown as described in the legend of Fig. 5 and treated with EGF, TGF- α , AR or HB-EGF (10 ng/ml) for 3, 6 or 24 hr. RNA was isolated and analyzed by RNase protection. The AR and 36B4 bands are indicated.

Fig. 10 HB-EGF mRNA levels on MCF-10A ras clones. MCF-10 parental cells and the derived ras clones were grown as described in the legend of Fig. 5. RNA was isolated and analyzed by RNase protection. The HB-EGF and 36B4 bands are indicated.

Fig. 11 AR mRNA levels on MCF-10A ras clones. MCF-10 parental cells and the derived ras clones were grown as described in the legend of Fig. 5. RNA was isolated and analyzed by RNase protection. The AR and 36B4 bands are indicated.

Fig. 12 Autophosphorylation of EGF and erbB-3 receptors after induction with EGF-related peptides. Panel A *Autophosphorylation of EGFR*. MCF-10A cells were grown as described in the legend of Fig. 5, treated with EGF, AR, HB-EGF, BTC or HRG- β 1 (100 ng/ml) for 10 min and levels of autophosphorylation of EGFR were determined as described in Experimental Procedures. Sizes are indicated in kilodaltons to the left. Panel B *Autophosphorylation of erbB-3*. MCF-10A cells were grown and treated

as described above and autophosphorylation levels of erbB-3 were determined. Sizes are indicated in kilodaltons to the left.

REFERENCES

- Barnard, J.A., Graves-Deal, R., Pittelkow, M.R., DuBois, R., Cook, P., Ramsey, G.W., Bishop, P.R., Damsstrup, L., and Coffey, R.J. (1994) Auto and cross-induction within the mammalian epidermal growth factor-related peptide family. *J. Biol. Chem.* **269**, 22817-22822
- Basolo, F., Elliot, J., Tait, L., Chen, X.Q., Maloney, T., Russo, I.H., Pauley, R., Morniki, S., Caamano, J., Klein-Szanto, A.J.P., Koszalka, M., and Russo J. (1991) Transformation of human breast epithelial cells by c-Ha-ras oncogene. *Mol. Carcinogen.* **4**, 25-31
- Bates, S.E., Davidson, N.E., Valverius, E.M., Freter, C.E., Dickson, R.B., Tam, J.P., Kudlow, J.E., Lippman, M.E., and Salomon, D.S. (1988) Expression of transforming growth factor- α and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance. *Mol. Endocrinol.* **2**, 543-555
- Beerli, R.R. and Hynes, N.E. (1996) Epidermal growth factor-related peptides activate distinct subsets of erbB receptors and differ in their biological activities. *J. Biol. Chem.* **271**, 6071-6076
- Besner, G.E., Whelton, D., Crissman-Combs, M.A., Steffen, C.L., Kim, G.Y., and Brigstock, D.R. (1992) Interaction of heparin-binding EGF-like growth factor (HB-EGF) with the epidermal growth factor receptor: modulation by heparin, heparinase, or synthetic heparin-binding HB-EGF fragments. *Growth Factors* **7**, 289-296
- Bjorge, J.D., Paterson, A.J., and Kudlow, J.E. (1989) Phorbol ester or epidermal growth factor (EGF) stimulates the concurrent accumulation of mRNA for the EGF receptor and its ligand transforming growth factor- α in a breast cancer cell line. *J. Biol. Chem.* **264**, 4021-4027
- Higashiyama, S., Abraham, J.A., Miller, J., Fiddes, J.C., and Klagsbrun, M. (1991) A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. *Science* **251**, 936-939

Kast, R., Fürstenberger, G., and Marks, F. (1993) Activation of cytosolic phospholipase A₂ by transforming growth factor- α in HEL-30 keratinocytes. *J. Biol. Chem.* **268**, 16795-16802

Lin, L.-L., Wartman, M., Lin, A.Y., Knopf, J.L., Seth, A., and Davis, R.J. (1993) cPLA₂ is phosphorylated and activated by MAP kinase. *Cell* **72**, 269-278

Martínez-Lacaci, I., Saceda, M., Plowman, G.D., Johnson, G.R., Normanno, N., Salomon, D.S., and Dickson, R.B. (1995) Estrogen and phorbol esters regulate amphiregulin expression by two separate mechanisms in human breast cancer cell lines. *Endocrinol.* **136**, 3983-3992

McCarthy, S.A., Samuels, M.L., Pritchard, C.A., Abraham, J.A., and McMahon, M. (1995) Rapid induction of heparin-binding epidermal growth factor/diphtheria toxin receptor expression by raf and ras oncogenes. *Genes and Development* **9**, 1953-1964

Pinkas-Kramarski, R., Soussan, L., Waterman, H., Levkowitz, G., Alroy, I., Klapper, L., Lavi, S., Seger, R., Ratzkin, B.J., Sela, M., and Yarden, Y. (1996) Diversification of neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. *EMBO J.* **15**, 2452-2467

Raab, G., Higashiyama, S., Hetelekidis, S., Abraham, J.A., Damm, D., Ono, M., and Klagsbrun, M. (1994) Biosynthesis and processing by phorbol ester of the cell surface-associated precursor form of heparin-binding EGF-like growth factor. *Biochem. Biophys. Res. Comm.* **204**, 592-597

Saceda, M., Lippman, M.E., Chambon, P., Lindsey, R.K., Ponglikitmongkol, M., Puente, M., and Martin, M.B. (1988) Regulation of the estrogen receptor in MCF-7 cells by estradiol. *Mol. Endocrinol.* **2**, 1157-1162

Schalkwijk, C.G., Spaargaren, M., Defize, L.H.K., Verkleu, A.J., Bosch, H. B., and Boonstra, J. (1995) Epidermal growth factor (EGF) induces serine phosphorylation-dependent activation and calcium-dependent translocation of the cytosolic phospholipase A₂. *Eur. J. Biochem.* **231**, 593-601

Wang, X.-N., Das, S.K., Damm, D., Klagsbrun, M., Abraham, J.A., and Dey, S.K. (1994) Differential regulation of heparin-binding epidermal growth factor-like growth factor in the adult ovariectomized mouse uterus by progesterone and estrogen. *Endocrinol.* **135**, 1264-1271

Zhang, Z., Funk, C., Roy, D., Glasser, S., and Mulholland, J. (1994) Heparin-binding epidermal growth factor-like growth factor is differentially regulated by progesterone and estradiol in rat uterine epithelial and stromal cells. *Endocrinol.* **134**, 1089-1094




FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5




FIGURE 6




FIGURE 7




FIGURE 8




FIGURE 9





FIGURE 10



FIGURE 11

a



b




FIGURE 12

CURRICULUM VITAE - DAVID SCOTT SALOMON

Present Status: Chief, Tumor Growth Factor Section
Laboratory of Tumor Immunology and Biology
National Cancer Institute
National Institutes of Health

Present Address: National Cancer Institute
National Institutes of Health
Building 10, Room 5B39
Bethesda, Maryland 20892
Telephone: (301) 496-9536

Date of Birth: [REDACTED]

Birthplace: [REDACTED]

Marital Status: [REDACTED]

Social Security Number: [REDACTED]

Education:

Ph.D. 1973 State University of New York, Albany, New York

B.A. 1969 Clark University, Worcester, Massachusetts

Previous Experience:

1992-Present Chief, Tumor Growth Factor Section, Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

1985- 1992 Research Biochemist, Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

1982 - 1985 Expert/Consultant, Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

1979 - 1982 Expert/Consultant, Laboratory of Pathophysiology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

1977 - 1979 Senior Staff Fellow, Laboratory of Developmental Biology and Anomalies, National Institutes of Health, Bethesda, Maryland

1975 - 1977 Staff Fellow, Laboratory of Developmental Biology and Anomalies, National Institute of Dental Research, National Institutes of Health, Bethesda, Maryland

1973 - 1975 Postdoctoral Fellow, Department of Cell Biology, Roche Institute of Molecular Biology, Nutley, New Jersey

1969 - 1973 Graduate Assistant, Department of Biological Sciences, State University of New York, Albany, New York

Honors, Scientific Accomplishments and Other Special Scientific Recognition:

1971 - 1973 National Institutes of Health Predoctoral Traineeship in Developmental Biology

1970 - 1971 State University of New York, Assistantship in Biochemistry

1990- U.S. Patent Application for:
CLONED HUMAN CRIPTO GENE AND APPLICATIONS THEREOF
Serial # 07/947,315
DHHS#E-027-90/1

1993- U.S. Patent Application for:
HUMAN CRIPTO-RELATED GENE
Serial # 08/154,198
DHHS#E-133-91/1

Membership in Professional Associations and Journals:

1988 - American Association for Cancer Research

1992 - American Society for Biochemistry and Molecular Biology

1993- Associate Editor, *Breast Cancer Research & Treatment*

1994- Associate Editor, *International Journal of Oncology*

1995- Associate Editor, *Topics in Mammary Gland Biology and Neoplasia*

1995- Associate Editor, *Cancer Reports Bulletin of the Tumor Institute of Naples*

BIBLIOGRAPHY

1. Salomon, D. and Mascarenhas, J. P.: Effect of adenosine 3',5'-cyclic monophosphate on the abscission of *Coleus* petioles. *Z. Pflanzenphysiol.* 65: 385-388, 1971.
2. Salomon, D. and Mascarenhas, J. P.: Auxin enhanced synthesis of adenosine 3',5' cyclic monophosphate in *Avena* coleoptile sections. *Life Sci.* 10: 879-883, 1971.
3. Salomon, D. and Mascarenhas, J. P.: Auxin and cyclic 3',5'-adenosine monophosphate during the isolation of chromatin from *Avena* coleoptiles: Effects on cell free RNA synthesis. *Biochem. Biophys. Res. Commun.* 47: 134-138, 1972.
4. Mascarenhas, J. P. and Salomon, D.: Cyclic 3',5'-adenosine monophosphate in *Avena* coleoptiles. *Proceedings of the 8th International Congress on Plant Growth Hormones*, 1972.
5. Salomon, D.: Adenosine 3',5'-cyclic monophosphate: Intermediate messenger in auxin action. Ph.D. Thesis. Thesis Abstracts, *University Microfilms*, Ann Arbor, MI, 1974.
6. Salomon, D. S. and Sherman, M. I.: Implantation and invasiveness of mouse blastocysts on uterine monolayers. *Exp. Cell Res.* 90: 261-268, 1975.
7. Sherman, M. I. and Salomon, D. S.: The relationship between the early mouse embryo and its environment. In Markert, C. L. and Papaconstantinou, J. (Eds.): *The Developmental Biology of Reproduction*. New York, Academic Press, 1975, pp. 277-309.
8. Marcal, J., Chew, N. J., Salomon, D. S., and Sherman, M. I.: $\Delta 5$, 3 β -hydroxysteroid dehydrogenase activities in rat trophoblast and ovary during pregnancy. *Endocrinology* 96: 1302-1308, 1975.
9. Salomon, D. S. and Sherman, M. I.: Biosynthesis of progesterone by cultured mouse midgestation trophoblast cells. *Dev. Biol.* 47-53: 394, 1975.
10. Salomon, D. S. and Sherman, M. I.: Gonadotrophin stimulation of progesterone synthesis by mouse ovarian cells in vitro. *Endocrinology* 99: 800-809, 1976.
11. Salomon, D. S. and Pratt, R. M.: Glucocorticoid receptors in embryonic facial mesenchyme cells. *Nature* 264: 174-177, 1976.
12. Sherman, M. I., Atrenza, S. B., Salomon, D. S., and Wudl, L. B.: Progesterone formation and metabolism by blastocysts and trophoblast cells in vitro. In Johnson, M. H. (Ed.): *Development in Mammals*. New York, North Holland Publishing Co., Vol. 2, 1977, pp. 209-235.
13. Salomon, D. S., Zubairi, Y., and Thompson, E. B.: Ontogeny and biochemical properties glucocorticoid receptors in midgestation mouse embryos. *J. Steroid Biochem.* 9: 95-107, 1978.
14. Salomon, D. S. and Pratt, R. M.: Inhibition of growth in vitro by glucocorticoids in mouse embryonic facial mesenchyme cells. *J. Cell. Physiol.* 97(3): 315-327, 1978.

15. Salomon, D. S., Gift, V. M., and Pratt, R. M.: Corticosterone levels in the maternal plasma and fetus of cleft palate sensitive and resistant mice. *Endocrinology* 104: 154-156, 1979.
16. Salomon, D. S. and Pratt, R. M.: Involvement of glucocorticoids in the development of the secondary palate: A review. *Differentiation* 13: 141-154, 1979.
17. Pratt, R. M., Figuora, A. A., Greene, R. M., and Salomon, D. S.: Alterations in macromolecular synthesis and function during abnormal palate development. In Persaud, T. V. N. (Ed.): *Abnormal Embryogenesis: Cellular and Molecular Aspects*. New York, MTP Press Ltd., 1979, pp. 161-176.
18. Salomon, D. S. and Vistica, D. T.: Steroid receptors and steroid response in cultured L1210 murine leukemia cells. *Mol. Cell. Endocrinol.* 13: 55-71, 1979.
19. Salomon, D. S., Verbruggen, L. A., and Paglia, L. M.: Hormone dependent growth of rat chondrosarcoma in vivo. *Cancer Res.* 39: 4387-4397, 1979.
20. Pratt, R. M. and Salomon, D. S.: Glucocorticoid receptors and cleft palate in mice and man. In Melnick, M., Bixlee, D., and Shields, E. D. (Eds.): *Progress in Clinical and Biological Research, "Etiology of Cleft Lip and Palate."* New York, Alan R. Liss, Vol. 46, 1980, pp. 149-169.
21. Hirata, F., Schiffman, E., Venkatasubramanian, K., Salomon, D., and Axelrod, J.: A phospholipase A₂ inhibitory protein in rabbit neutrophils induced by glucocorticoids. *Proc. Natl. Acad. Sci. USA* 77: 2533-2536, 1980.
22. Kidwell, W. R., Wicha, M. S., Salomon, D. S., and Liotta, L. A.: Hormonal controls of collagen substratum formation by cultured mammary cells: Implications for growth and differentiation. In Jimenez de Asua, L., et al. (Eds.): *Control Mechanisms in Animal Cells*. New York, Raven Press, 1980, pp. 333-340.
23. Salomon, D. S.: Growth of mouse embryonal carcinoma cells in serum-free, hormone supplemented medium correlated with receptors for growth factors. *Exp. Cell Res.* 128(2): 311-327, 1980.
24. Erickson, R. E., Pratt, R. M., Salomon, D. S., Brown, K. E., and Diewert, V.: Steroid-induced cleft palate in the brachymorphic mouse. *Mutagenesis, Carcinogenesis and Teratogenesis* 1(1): 15-24, 1980.
25. Verbruggen, L. A. and Salomon, D. S.: Glucocorticoid receptors and inhibition of neonatal mouse dermal fibroblast growth in primary culture. *Arch. Dermatol. Res.* 269: 111-126, 1980.
26. Salomon, D. S. and Pratt, R. M.: Glucocorticoid receptors and cleft palate in the mouse. In Pratt, R. M. and Christiansen, R. (Eds.): *Current Trends in Prenatal Craniofacial Development*. New York, Elsevier/North Holland, 1980, pp. 367-386.
27. Pratt, R. M., Yoneda, T., Silver, M. H., and Salomon, D. S.: Involvement of glucocorticoids and epidermal growth factor in secondary palate development. In Pratt, R. M. and Christiansen, R. (Eds.): *Current Trends in Prenatal Craniofacial Development*. New York, Elsevier/North Holland, 1980, pp. 236-252.

28. Kidwell, W. R., Wicha, M. S., Salomon, D. S., and Liotta, L. A.: Differential recognition of basement membrane collagen by normal and neoplastic mammary cells. In McGrath, C. M., Brennan, M. J., and Rich, M. A. (Eds.): *Cell Biology of Breast Cancer*. New York, Academic Press, 1980, pp. 17-33.
29. Salomon, D. S., Liotta, L. A., and Kidwell, W. R.: Differential response to growth factor by rat mammary epithelium plated on different collagen substrata in serum-free medium. *Proc. Natl. Acad. Sci. USA* 78: 382-386, 1981.
30. Pratt, R. M. and Salomon, D. S.: Biochemical basis for the teratogenic effects of glucocorticoids. In Juchau, M. R. (Ed.): *The Biochemical Basis of Chemical Teratogenesis*. New York, Elsevier/North Holland, 1981, pp. 179-199.
31. Sando, J. J., Hilfiker, M. L., Salomon, D. S., and Farrar, J. J.: Evidence that specific receptors mediate phorbol ester-enhanced production of T cell growth factor. *Proc. Natl. Acad. Sci. USA* 78(2): 1189-1193, 1981.
32. Sim, R. P., Salomon, D. S., Nylen, M. U., and Pratt, R. M.: Tumor promoter TPA mimics epidermal growth factor-induced precocious tooth eruption in the rodent. *Mutagenesis, Carcinogenesis and Teratogenesis* 1: 361-365, 1981.
33. Greene, R. M. and Salomon, D. S.: Glutamine synthetase activity in the developing rodent secondary palate and induction by dexamethasone. *Cell Differ.* 10: 193-201, 1981.
34. Salomon, D. S.: Inhibition of epidermal growth factor binding to mouse embryonal carcinoma cells by phorbol esters mediated by specific receptors for phorbol esters. *J. Biol. Chem.* 256: 7958-7966, 1981.
35. Verbruggen, L. A., Salomon, D. S., and Greene, R. M.: Inhibition of collagen and sulfated glycosaminoglycan synthesis in neonatal mouse dermal fibroblasts by corticosterone. *Biochem. Pharmacol.* 30: 3285-3289, 1981.
36. Salomon, D. S., Liotta, L. A., Foidart, J.-M., and Yaar, M.: Synthesis and turnover of basement membrane components by mouse embryonal carcinoma cells in serum-free, hormone-supplemented medium. In Sato, G. H., Pardee, A. B., and Sirbasku, D. A. (Eds.): *Cold Spring Harbor Symposium on Cell Proliferation-Growth of Cells in Hormonally Defined Media*. Cold Spring Harbor, NY, Cold Spring Harbor Press, Book A, Vol. 9, 1982, pp. 203-207.
37. Kidwell, W. R., Salomon, D. S., Liotta, L. A., Zwiebel, J. A., and Bano, M.: Growth factor effects on mammary epithelial cell proliferation and basement membrane synthesis. In Sato, G. H., Pardee, A. B., and Sirbasku, D. A. (Eds.): *Cold Spring Harbor Symposium on Cell Proliferation-Growth of Cells in Hormonally Defined Media*. Cold Spring Harbor, NY, Cold Spring Harbor Press, Book B, Vol. 9, 1982, pp. 807-818.
38. Salomon, D. S., Liotta, L. A., Rennard, S. I., Terranova, V., Foidart, J.-M., and Yaar, M.: Stimulation by retinoic acid of synthesis and turnover of basement membrane in mouse embryonal carcinoma-derived endoderm cells. *Coll. Relat. Res.* 2: 93-110, 1982.
39. Salomon, D. S., Bano, M., Smith, B. B., and Kidwell, W. R.: Isolation and characterization of a growth factor (embryonin) from bovine fetuin and its resemblance to α_2 -macroglobulin. *J. Biol. Chem.* 257: 14093-14101, 1982.

40. Zwiebel, J. A., Davis, M. R., Kohn, E., Salomon, D. S., and Kidwell, W. R.: Anchorage-independent growth-conferring factor production by rat mammary tumor cells. *Cancer Res.* 42: 5117-5125, 1982.
41. Sahai, A., Smith, K. B., Panneerselvam, M., and Salomon, D. S.: Activation of calcium and phospholipid-dependent protein kinase by epidermal growth factor in A431 cells: Attenuation by 12-O-tetradecanoylphorbol-13-acetate. *Biochem. Biophys. Res. Commun.* 109: 1206-1214, 1982.
42. Salomon, D. S.: Hormone receptors and malformations. In Kochhar, D. M. and Johnson, E. M. (Eds.): *Handbook of Experimental Pharmacology: Teratogenesis and Reproductive Toxicology*. New York, Springer-Verlag, Vol. 65, 1983, pp. 113-136.
43. Bano, M., Zwiebel, J. A., Salomon, D. S., and Kidwell, W. R.: Detection and partial characterization of collagen synthesis stimulating activities in rat mammary adenocarcinomas. *J. Biol. Chem.* 258: 2729-2735, 1983.
44. Smith, K. B., Losonczy, I., Sahai, A., Panneerselvam, M., Fehnel, P., and Salomon, D. S.: Effect of 12-O-tetradecanoylphorbol-13-acetate (TPA) on the growth inhibitory and increased phosphatidylinositol response induced by epidermal growth factor (EGF) in A431 cells. *J. Cell. Physiol.* 117: 91-100, 1983.
45. Salomon, D. S., Liotta, L. A., Panneerselvam, M., Terranova, V. P., Sahai, A., and Fehnel, P.: Synthesis and turnover of basement membrane components by mouse embryonal carcinoma and human A431 epidermoid carcinoma cells in serum-free medium. In Barnes, D. W., Sirbasku, D. A., and Sato, G. H. (Eds.): *Cell Culture Methods for Molecular and Cell Biology. Methods for Preparation of Media, Supplements and Substrata for Serum-Free Animal Cell Culture*. New York, Alan R. Liss, Inc., Vol. 1, 1984, pp. 295-320.
46. Verbruggen, L. A., Orloff, S., Rao, V. H., and Salomon, D. S.: Relationship of cell growth to collagen synthesis in glucocorticoid treated A/J and C57BL/6/J neonatal mouse dermal fibroblasts. *Scand. J. Rheumatol.* 12: 360-366, 1983.
47. Kidwell, W. R., Bano, M., Zwiebel, J., and Salomon, D. S.: Growth of mammary epithelial cells on collagen substratum in serum-free medium. In Barnes, D. W., Sirbasku, D. A., and Sato, G. H. (Eds.): *Cell Culture Methods for Molecular and Cell Biology. Methods for Preparation of Media, Supplements and Substrata for Serum-Free Animal Cell Culture*. New York, Alan R. Liss, Inc., Vol. 2, 1984, pp. 105-125.
48. Salomon, D. S., Smith, K. B., Losonczy, I., Bano, M., Kidwell, W. R., Alessandri, G., and Gullino, P. M.: Alpha-2-macroglobulin, a contaminant of commercially prepared Pedersen fetuin: Isolation, characterization and biological activity. In Barnes, D. W., Sirbasku, D. A., and Sato, G. H. (Eds.): *Cell Culture Methods for Molecular and Cell Biology. Methods for Preparation of Media, Supplements and Substrata for Serum-Free Animal Cell Culture*. New York, Alan R. Liss, Inc., Vol. 3, 1984, pp. 125-153.
49. Salomon, D. S., Zwiebel, J. A., Bano, M., Losonczy, I., Fehnel, P., and Kidwell, W. R.: Presence of transforming growth factors in human breast cancer cells. *Cancer Res.* 44: 4069-4077, 1984.
50. Salomon, D. S., Zwiebel, J. A., Noda, M., and Bassin, R. H.: Flat revertants derived from Kirsten murine sarcoma virus transformed cells produce transforming growth factors. *J. Cell. Physiol.* 121: 22-31, 1984.

51. Feuerstein, N., Sahai, A., Anderson, W. B., Salomon, D. S., and Cooper, H. L.: Differential phosphorylation events associated with phorbol ester effects on acceleration versus inhibition of cell growth. *Cancer Res.* 44: 5227-5234, 1984.
52. Bano, M., Salomon, D. S., and Kidwell, W. R.: Purification of a mammary-derived growth factor (MDGF_F) from human milk and human mammary tumors. *J. Biol. Chem.* 260: 5745-5752, 1985.
53. Hand, P. H., Colcher, D., Salomon, D. S., Ridge, J., Noguchi, P., and Schlom, J.: Spatial configuration of carcinoma cell population influences the expression of a tumor-associated glycoprotein. *Cancer Res.* 45: 833-840, 1985.
54. Panneerselvam, M., Sahai, A., Fehnel, P., and Salomon, D. S.: Modulation of type IV collagen and laminin production in A431 human squamous epidermoid carcinoma cells by 12-O-tetradecanoylphorbol-13-acetate (TPA) and epidermal growth factor (EGF). *Arch. Dermatol. Res.* 277(8): 377-383, 1985.
55. Anderson, W. B. and Salomon, D. S.: Calcium, phospholipid-dependent protein kinase C as a cellular receptor for phorbol ester tumor promoters: Possible role in modulating cell growth and tumor promotion. In Kuo, J. F. (Ed.): *CRC in Biochemistry, Phospholipids and Cellular Regulation*. Boca Raton, FL, CRC Press Inc., Vol. 2, 1985, pp. 127-170.
56. Zwiebel, J. A., Bano, M., Salomon, D. S., Nexø, E., and Kidwell, W. R.: Partial purification of transforming growth factors from human milk. *Cancer Res.* 46: 933-939, 1986.
57. Kidwell, W. R., Bano, M., Burdette, K., Losonczy, I., and Salomon, D. S.: Mammary-derived growth factors in human milk. In Jensen, R. G. and Neville, M. C. (Eds.): *Human Lactation. Milk Components and Methodologies*. New York, Plenum Publishing Co., 1985, pp. 209-219.
58. Salomon, D. S. and Perroteau, I.: Growth factors in cancer and their relationship to oncogenes. *Cancer Invest.* 44: 43-60, 1986.
59. Salomon, D. S., Bano, M., and Kidwell, W. R.: Polypeptide growth factors and the growth of mammary epithelial cells. In Rich, M. A., Hayer, J. C., and Papadimitriou, J. T. (Eds.): *Breast Cancer: Origins, Detection and Treatment*. Boston, Martinus Nijhoff, Inc., 1986, pp. 42-56.
60. Sahai, A., Feuerstein, N., Cooper, H. L., and Salomon, D. S.: Effect of epidermal growth factor (EGF) and 12-O-tetradecanoylphorbol-13-acetate (TPA) on the phosphorylation of soluble acidic proteins in A431 epidermoid carcinoma cells. *Cancer Res.* 46: 4143-4150, 1986.
61. Salomon, D. S., Perroteau, I., and Kidwell, W. R.: Tumor-derived growth factors in rodent and human mammary carcinoma cells. In Eckhardt, S., Holaner, J. H., and Nagel, G. A. (Eds.): *Contributions to Oncology*. Basel, Switzerland, S. Karger, Inc., 1986, pp. 5-16.
62. Salomon, D. S. and Perroteau, I.: Oncological aspects of growth factors. *Annu. Rep. Medicinal Chem.* 21: 159-168, 1986.

63. Salomon, D. S., Perroteau, I., Kidwell, W. R., Tam, J., and Derynck, R.: Loss of growth responsiveness to epidermal growth factor and enhanced production of alpha transforming growth factors in *ras* transformed mouse mammary epithelial cells. *J. Cell. Physiol.* 130: 397-409, 1987.
64. Perroteau, I., Salomon, D. S., DeBortoli, M., Kidwell, W. R., Pardue, R., Dedman, J., and Tam, J.: Immunological detection and quantitation of alpha transforming growth factors in human breast carcinoma cells. *Breast Cancer Res. Treat.* 7: 201-210, 1986.
65. Liu, S., Sanfilippo, B., Perroteau, I., Derynck, R., Salomon, D. S., and Kidwell, W. R.: Expression of transforming growth factor alpha (TGF α) in differentiated rat mammary tumors: Estrogen induction of TGF α production. *Mol. Endocrinol.* 1(10): 683-692, 1987.
66. Salomon, D., Bano, M., and Kidwell, W. R.: Polypeptide growth factors and the growth of mammary epithelial cells. *Dev. Oncol.* 43: 42-56, 1986.
67. Kidwell, W. R. and Salomon, D. S.: Growth factors in human milk: Sources and potential physiological roles. In Atkinson, S. A. and Lonerdol, B. (Eds.): *CRC, Protein and Non-Protein Nitrogen in Human Milk*. Boca Raton, FL, CRC Press Inc., pp. 78-91, 1989.
68. Cooper, H. L., Bhattacharya, B., Bassin, R. H., and Salomon, D. S.: Suppression of synthesis and utilization of tropomyosin in mouse and rat fibroblasts by alpha transforming growth factor: A pathway in oncogene action. *Cancer Res.* 47: 4493-4500, 1987.
69. Kidwell, W. R., Salomon, D. S., and Mohanam, S.: Production of growth factors by normal human mammary cells in culture. In Goldman, A., Atkinson, S., and Hanson, L. A. (Eds.): *Effect of Human Milk on the Recipient Infant*. New York, Plenum Press, 1987, pp. 227-239.
70. Tam, J. P., Sheikh, M. A., Salomon, D. S., and Ossowski, L.: An efficient synthesis of human alpha transforming growth factor: Its physical and biological characterization. *Proc. Natl. Acad. Sci. USA* 83: 8082-8086, 1986.
71. Ciardiello, F., Sanfilippo, B., Yanagihara, K., Kim, N., Tortora, G., Bassin, R. H., Kidwell, W. R., and Salomon, D. S.: Differential growth sensitivity to 4-*cis*-hydroxy-L-proline of transformed rodent cell lines. *Cancer Res.* 48: 2483-2491, 1988.
72. Kidwell, W. R., Johanam, S., and Salomon, D. S.: Growth factor production by mammary tumor cells. In Medina, D., Kidwell, W. R., Heppner, G., and Andersen, E. (Eds.): *Cellular and Molecular Biology of Mammary Cancer*. New York, Plenum Press, 1987, pp. 239-252.
73. Sanfilippo, B., Ciardiello, F., Salomon, D. S., and Kidwell, W. R.: Growth of cells on a perfluorocarbon medium interphase: A quantitative assay for anchorage-independent cell growth. *In Vitro* 24: 71-78, 1988.
74. Kidwell, W. R., Mohanam, S., Sanfilippo, B., and Salomon, D. S.: Tissue organization and cancer: Role of autocrine growth factors in extracellular matrix biosynthesis. In Lippman, M. E. (Ed.): *Proceedings of the 16th Annual UCLA Symposium on Cellular and Molecular Biology. Growth Regulation of Cancer*. New York, Alan R. Liss, Inc., Vol. 74, 1988, pp. 145-150.

75. Bates, S. E., Davidson, N. E., Valverius, E., Dickson, R. B., Freter, C. E., Tam, J. P., Kudlow, J. E., Lippman, M. E., and Salomon, D. S.: Expression of transforming growth factor alpha and its mRNA in human breast cancer: Regulation by estrogen and its possible functional significance. *Mol. Endocrinol.* 2: 543-555, 1988.
76. Salomon, D. S. and Kidwell, W. R.: Tumor-associated growth factors in malignant rodent and human mammary epithelial cells. In McGuire, W. L., Lippman, M. E., and Dickson, R. B. (Eds.): *Breast Cancer: Cellular and Molecular Biology*. Boston, Kluwer Academic Publishers, 1988, pp. 363-391.
77. Bhattacharya, B., Ciardiello, F., Salomon, D. S., and Cooper, H. L.: Disordered metabolism of microfilament proteins, tropomyosin and actin, in mouse mammary epithelial cells expressing the Ha-ras oncogene. *Oncogene Res.* 3: 51-65, 1988.
78. Salomon, D. S., Kidwell, W. R., Kim, N., Ciardiello, F., Bates, S. E., Valverius, E., Lippman, M. E., Dickson, R. B., and Stampfer, M.: Modulation by estrogen and growth factors of transforming growth factor alpha (TGF α) expression in normal and malignant human mammary epithelial cells. *Recent Results in Cancer Res.* 113: 57-69, 1989.
79. Mohanam, S., Salomon, D. S., and Kidwell, W. R.: Substratum modulation of epidermal growth factor receptor expression by normal mouse mammary cells. *J. Am. Dairy Sci. Assoc.* 71: 1507-1514, 1988.
80. Ciardiello, F., Kim, N., Hynes, N., Jaggi, R., Redmond, S., Liscia, D. S., Sanfilippo, B., Merlo, G., Callahan, R., Kidwell, W. R., and Salomon, D. S.: Induction of transforming growth factor alpha expression in mouse mammary epithelial cells after transformation with a point-mutated c-Ha-ras proto-oncogene. *Mol. Endocrinol.* 2: 1202-1215, 1988.
81. Stracke, M. L., Kohn, E. C., Aznavoorian, S. A., Wilson, L. L., Salomon, D. S., Kruttsch, H. C., Liotta, L. A., and Schiffmann, E.: Insulin-like growth factors stimulate chemotaxis in human melanoma cells. *Biochem. Biophys. Res. Commun.* 153: 1076-1083, 1988.
82. Kidwell, W. R. and Salomon, D. S.: Mammary tumor associated growth factors: Origins and possible functions. In Rich, H. A., Hager, J. C., and Lopez, D. M. (Eds.): *Breast Cancer: Scientific and Clinical Progress*. Boston, Kluwer Academic Publishers, 1988, pp. 42-54.
83. Dickson, R. B., Bates, S. E., Valverius, E., Knabbe, C., Salomon, D., Huff, K. K., Bronzert, D., Walker-Jones, D., Freter, C., Favoni, R., Yee, D., Zugmaier, G., Ennis, B., Clarke, R., Kern, F., Roren, N., and Lippman, M. E.: Estrogen and antiestrogen regulation of mitogenic growth factors in human breast cancer cells. In Bresciani, F., King, R. S. B., Lippman, M. E., and Raymund, J. P. (Eds.): *Progress in Cancer Research and Therapy*. New York, Raven Press, Vol. 35, 1988, pp. 217-222.
84. Shankar, V., Ciardiello, F., Kim, N., Derynck, R., Liscia, D. S., Merlo, G., Langton, B. C., Sheer, D., Callahan, R., Bassin, R. H., Lippman, M. E., Hynes, N., and Salomon, D. S.: Transformation of an established mouse mammary epithelial cell line following transfection with a human transforming growth factor alpha cDNA. *Mol. Carcinogenesis* 2: 1-11, 1989.

85. Tortora, G., Ciardiello, F., Ally, S., Clair, T., Salomon, D. S., and Cho-Chung, Y. S.: Site-selective 8-chloro adenosine 3',5'-cyclic monophosphate inhibits transformation and transforming growth factor production in Ki-ras transformed rat fibroblasts. *FEBS Lett.* 242: 363-367, 1989.
86. Ciardiello, F., Hynes, N., Kim, N., Valverius, E., Lippman, M. E., and Salomon, D. S.: Transformation of mouse mammary epithelial cells with the Ha-ras but not with the neu oncogene results in a gene dosage-dependent increase in transforming growth factor-production. *FEBS Lett.* 250: 474-478, 1989.
87. Ciardiello, F., Kim, N., Liscia, D. S., Bianco, C., Lidereau, R., Merlo, G., Callahan, R., Brattain, M., Greiner, J., Szpak, C., Kidwell, W., Derynck, R., Schlom, J., and Salomon, D. S.: Transforming growth factor α (TGF α) mRNA expression in human breast carcinomas and TGF α activity in the effusions of breast cancer patients. *J. Natl. Cancer Inst.* 81: 1165-1171, 1989.
88. Valverius, E. M., Bates, S. E., Stampfer, M. R., Clark, R., McCormick, F., Salomon, D. S., Lippman, M. E., and Dickson, R. B.: Transforming growth factor α production and epidermal growth factor receptor expression in normal and oncogene transformed human mammary epithelial cells. *Mol. Endocrinol.* 3: 203-214, 1989.
89. Ciardiello, F., Valverius, E. M., Colucci-D'Amato, G. L., Kim, N., Bassin, R. H., and Salomon, D. S.: Differential growth factor expression in transformed NIH-3T3 cells. *J. Cell. Biochem.* 42: 45-57, 1990.
90. Bhattacharya, B., Prasad, G. L., Valverius, E. M., Salomon, D. S., and Cooper, H. L.: Tropomyosins of human mammary epithelial cells: Consistent defects of expression in mammary carcinoma cell lines. *Cancer Res.* 50: 2105-2112, 1990.
91. Thor, A., Salomon, D. S., Merlo, G., Liscia, D., Lidereau, R., Callahan, R. C., Schlom, J., and Ali, I.: Genetic abnormalities in breast carcinoma. *Surgical Pathol.* 5: 331-348, 1994.
92. McGeady, M. L., Kerby, S., Shankar, V., Ciardiello, F., Salomon, D. S., and Seidman, M.: Infection with a TGF α retroviral vector transforms normal mouse mammary epithelial cells but not normal rat fibroblasts. *Oncogene* 4: 1375-1382, 1989.
93. Salomon, D. S., Ciardiello, F., Valverius, E. M., and Kim, N.: The role of *ras* gene expression and transforming growth factor α production in the etiology and progression of rodent and human breast cancer. In W. L., Lippman, M. E., and Dickson, R. B. (Eds.): *Regulatory Mechanisms in Breast Cancer*. Boston, Kluwer Academic Publishers. pg. 107-157, 1990.
94. Liscia, D. S., Merlo, G., Ciardiello, F., Kim, N., Smith, G. H., Callahan, R. H., and Salomon, D. S.: Transforming growth factor- messenger RNA localization in the developing adult rat and human mammary gland by *in situ* hybridization. *Dev. Biol.* 140: 123-131, 1990.
95. Salomon, D. S., Ciardiello, F., Valverius, E., Saeki, T., and Kim, N.: Transforming growth factors in human breast cancer. *Biomed. Pharmacother.* 43: 661-667, 1989.

96. Ciardiello, F., Tortora, G., Kim, N., Clair, T., Ally, S., Salomon, D. S., and Cho-Chung, Y. S.: 8-Chloro-cAMP inhibits transforming growth factor α transformation of mammary epithelial cells by restoration of normal mRNA patterns for cAMP-dependent protein kinase regulatory subunit isoforms which show disruption upon transformation. *J. Biol. Chem.* 265: 1016-1020, 1990.
97. Blondel, B., Talbot, N., Merlo, G. R., Wychowski, C., Yokozaki, H., Valverius, E. M., Salomon, D. S., and Bussin, R. H.: Efficient induction of focus formation in a subclone of NIH3T3 cells by c-myc and its inhibition by serum and growth factors. *Oncogene* 5: 857-866, 1990.
98. Valverius, E. M., Velu, T., Shankar, V., Ciardiello, F., Kim, N., and Salomon, D. S.: Overexpression of the epidermal growth factor receptor in human breast cancer cells fails to induce an estrogen-independent phenotype. *Int. J. Cancer* 46: 712-718, 1990.
99. Ciardiello, F., Kim, N., McGeady, M. L., Liscia, D. S., Saeki, T., Bianco, C., and Salomon, D. S.: Expression of transforming growth factor alpha (TGF α) in normal and malignant mouse and human mammary epithelial cells and TGF α in the pleural effusion of breast cancer patients. *Ann. Oncol.* 2: 169-182, 1991.
100. Hynes, N. E., Taverna, D., Harweth, I. M., Ciardiello, F., Salomon, D. S., Yamamoto, T., and Groner, B.: Oncogene transfer into cultured mouse mammary epithelial cells: Tumorigenesis and interference with lactogenic hormone action. *Mol. Cell. Biol.* 10: 4027-4034, 1990.
101. Ciardiello, F., McGeady, M. L., Kim, N., Basolo, F., Hynes, N., Langton, B., Yokozaki, H., Saeki, T., Elliot, J. W., Masui, H., Mendelsohn, J., Soule, H., Russo, J., and Salomon, D.: TGF α expression is enhanced in human mammary epithelial cells transformed by an activated c-Ha-ras proto-oncogene but not by the c-neu protooncogene and overexpression of the TGF α cDNA leads to transformation. *Cell Growth and Differentiation* 1: 407-420, 1990.
102. Merlo, G. R., Blondel, B. J., Deed, R., MacAllan, D., Peters, G., Dickson, C., Liscia, D. S., Ciardiello, F., Valverius, E. M., Salomon, D. S., and Callahan, R.: The mouse int-2 gene exhibits basic fibroblast growth factor (bFGF) activity in a bFGF-responsive cell line. *Cell Growth and Differentiation* 1: 463-472, 1990.
103. Valverius, E. V., Ciardiello, F., Heldin, N-E., Blondel, B., Merb, G., Smith, G., Starnpfer, M. R., Lippman, M. E., Dickson, R. B., and Salomon, D. S.: Stromal influences on transformation of human mammary epithelial cells expressing c-myc or SV40T. *J. Cell. Physiol* 145: 207-216, 1990.
104. Yanagihara, K. Ciardiello, F., Talbot, N., McGeady, M.L., Cooper, H., Benade, L., Salomon, D. S. and Bassin, R. H.: Isolation of a new class of "flat" revertants from ras-transformed NIH 3T3-cells using cis-4-hydroxy-L-proline. *Oncogene* 5: 1178-1186, 1990.
105. Salomon, D. S., Kim, N., Saeki, T., Ciardiello, F.: Transforming growth factor- α : An oncodevelopmental growth factor. *Cancer Cells* 2: 389-397, 1990.
106. Ciardiello, F., Dono, R., Kim, N., Persico, M.G., and Salomon, D.S.: Expression

of cripto, a novel gene of the epidermal growth factor gene family, leads to *in vitro* transformation of a normal mouse mammary epithelial cell line. *Cancer Res.* 51: 1051-1054, 1991.

107. Colletta, G., Cirafici, A. M., Di Carlo, A., Ciardiello, F., Salomon, D. S., Vecchio, G.: Constitutive expression of transforming growth factor α does not transform rat thyroid epithelial cells. *Oncogene.* 6: 583-587, 1991.
108. Ciardiello, F., Kim, N., Saeki, T., Donas, R., Persico, M.G., Plowman, G.D., Garrigues, J., Radke, S., Todaro, G.J., and Salomon, D.S.: Differential expression of epidermal growth factor-related proteins in human colorectal tumors. *Proc. Nat'l Acad. Sci. USA* 88: 7792-7796, 1991.
109. Kuniyasu, H., Yoshida, K., Yokosaki, H., Yasui, W., Ito, H., Toge, T., Persico, M.G., Saeki, T., Salomon, D.S., and Tahara, E.: Expression of cripto, a novel growth factor in human gastrointestinal carcinomas. *Jap. Journal Cancer Res.* 82: 969-973, 1991.
110. Johnson, G.R., Saeki, T., Auersperg, N., Gordon, A.W., Shoyab, M., Salomon, D.S., and Stromberg, C.: Response to an expression of amphiregulin ovarian carcinoma and normal ovarian surface epithelial cells: Nuclear localization of endogenous amphiregulin. *Biochem. Biophys. Res. Commun.* 180: 481-488, 1991.
111. Saeki, T., Cristiano, A., Lynch, M.J., Brattain, M., Kim, N., Normanno, N., Kenney, N., Ciardiello, F., and Salomon, D.S.: Regulation by estrogen through the 5'-flanking region of the transforming growth factor α gene. *Mol. Endo.* 5: 1955-1964, 1991.
112. Venesio, T., Taverna, D., Hynes, N., Deed, R., MacAllan, D., Ciardiello, F., Valverius, E., Salomon, D.S., Callahan, R., and Merlo, G.: The *int-2* gene product acts as a growth factor and substitutes for basic fibroblast growth factor in promoting the differentiation of a normal mammary epithelial cell line. *Cell Growth and Differentiation* 3: 63-71, 1992.
113. Ciardiello, F., Gottardis, M., Basolo, F., Pepe, S., Normanno, N., Dickson, R.B., Bianco, R.A., and Salomon, D.S.: Additive effects of *c-erb B-2*, *c-Ha-ras* and transforming growth factor α genes on the *in vitro* transformation of human mammary epithelial cells. *Mol. Carcinogenesis* 6: 43-52, 1992.
114. Saeki, T., Stromberg, K., Qi, C-F., Gullick, W.J., Tahara, E., Normanno, N., Ciardiello, F., Kenney, N., Johnson, G., and Salomon, D.S.: Differential immunohistochemical detection of amphiregulin and cripto in human normal colon and colorectal tumors. *Cancer Res.* 52: 3467-3473, 1992.
115. Johnson, G.R., Saeki, T., Gordon, A.W., Shoyab, M., Salomon, D.S., and Stromberg, K.: Autocrine action of amphiregulin in a colon carcinoma cell line and immunocytochemical localization of amphiregulin in human colon using antipeptide antibodies. *J. Cell. Biol.* 118: 741-751, 1992.
116. Salomon, D.S., Dickson, R.B., Normanno, N., Saeki, T., Kim, N., Kenney, N., and Ciardiello, F.: Current Perspectives on Molecular and Cellular Oncology. Vol. 1, Part B, D.A. Spandidos, ed., Interaction of oncogenes and growth factors in colon and breast cancer. *JAI Press Ltd*, London pp. 211-261, 1992.
117. Dickson, R.B., Salomon, D.S., and Lippman, M.E.: Tyrosine kinase receptor-nuclear protooncogene interactions in breast cancer. *Cancer Treat. Res.* 61:249-273, 1992.

118. Ciardiello, F., Bianco, C., Normanno, N., Baldassare, G., Pepe, S., Tootora, G., Bianco, A.R., and Salomon, D.S.: Infection with a transforming growth factor α antisense retroviral expression vector reduces the in vitro growth and transformation of a human colon cancer cell line. *Int. J. of Cancer* 54:952-958, 1993.
119. Normanno, N., Qi, C.-F., Gullick, W.J., Persico, G., Yarden, Y., Wen, D., Plowman, G., Kenney, N., Johnson, G., Kim, N., Brandt, R., Martinez-Lacaci, I., Dickson, R.B., and Salomon, D.C.: Expression of amphiregulin, cripto-1, and heregulin α in human breast cancer cells. *Int. J. Oncol.* 2:903-911, 1993.
120. Kenney, N., Johnson, G., Selvam, M.P., Kim, N., Qi, F.-F., Saeki, T., Brandt, R., Jones, B.-W., Ciardiello, F., Shoyab, M., Plowman, G., Day, A., Salomon, D.S., and Normanno, N.: Transforming growth factor α (TGF α) and amphiregulin (AR) as autocrine growth factors in nontransformed immortalized 184A1N4 human mammary epithelial cells. *Mol. Cell. Diff.* 1(2): 163-184, 1993.
121. Kenney, N., Saeki, T., Gottardis, M., Garcia-Morales, P., Martin, M.-B., Racheffort, H., Normanno, N., Kim, N., Ciardiello, F., and Salomon, D.S.: Expression of transforming growth factor α (TGF α) antisense mRNA inhibits estrogen-induced production of TGF α and estrogen-induced production of TGF α and estrogen-induced growth of estrogen-responsive human breast cancer cells. *J. Cell. Physiol.* 156: 497-514, 1993.
122. Diella, F., Normanno, N., Merlo, G., Salomon, D.S., and Callahan, R.: Absence of p53 mutations in nontransformed human mammary epithelial cell lines. *Life Sci. Adv. Biochem.* 12: 47-51, 1993.
123. Callahan, R.C. and Salomon, D.S.: Oncogenes, Tumour Suppressor Genes and Growth Factors in Breast Cancer: Novel Targets for Diagnosis, Prognosis and Therapy. In: *Cancer Surveys* 18: Breast Cancer 35-56, 1993.
124. Normanno, N., Selvan, M.P., Saeki, T., Johnson, G., Brandt, R., Kim, N., Ciardiello, F., Shoyab, M., Plowman, G., Todaro, G., and Salomon, D.S.: Amphiregulin as an autocrine growth factor for c-Ha-ras and c-erb B-2 transformed human mammary epithelial cells. *Proc. Natl. Acad. Sci. USA* 91: 2790-2794, 1994.
125. Ciardiello, F., Tortora, G., Bianco, C., Selvam, M.P., Basolo, F., Fontanini, G., Pacifico, F., Normanno, N., Brandt, R., Persico, M.G., Salomon, D.S., and Bianco, R.A.: Inhibition of CRIPTO expression and tumorigenicity in human colon cancer cells by antisense RNA and oligodeoxynucleotides. *Oncogene* 9:291-298, 1994.
126. Bianco, C., Tortora, G., Basolo, F., Fiore, L., Fontanini, G., Merlo, G., Salomon, D.S., Bianco, A.R., and Ciardiello, F.: Effects of mutant p53 genes on transformation of human mammary epithelial cells. *Int. J. Oncol.* 4:1077-1082, 1994.
127. Normanno, N., Ciardiello, F., Brandt, R., and Salomon, D.S.: Epidermal growth factor-related peptides in the pathogenesis of breast cancer. *Breast Cancer Res. & Treat.* 29:11-27, 1994.
128. Brandt, R., Normanno, N., Gullick, W.J., Lin, Jiing-Huey, Harkins, R., Schneider, D., Jones, B.-W., Ciardiello, F., Persico, M.G., Armenante, F., Kim, N., and Salomon, D.S.: Identification and biological characterization of an epidermal growth factor-related protein: Cripto-1. *J. Biol. Chem.* 269: 17320-17328, 1994.

129. Qi, C.-F., Liscia, D.S., Merlo, G., Normanno, N., Johnson, G., Gullick, W.J., Ciardiello, F., Brandt, R., Kim, N., Kenney, N., and Salomon, D.S.: Expression of transforming growth factor α , amphiregulin, and crip-1 in human breast carcinomas. *British J. Cancer* 69: 903-910, 1994.
130. Garcia-Morales, P., Saceda, M., Kenney, N., Kim, N., Salomon, D.S., Gottardis, M.M., Solomon, H.B., Sholler, P.F., Jordan, V.V., and Martin, M.B.: Effect of cadmium on estrogen receptor levels and estrogen-induced responses in human breast cancer cells. *J. Biol. Chem.* 269: 16896-16901, 1994.
131. Saeki, T., Salomon, D.S., Normanno, N., Johnson, G. R., Gullick, W.J., Mandai, K., Moriwaki, S., Takashima, S., Kuniyasu, M., Tahara, E., Kawami, H., Nishiyama, M., and Toge, T.: Immunohistochemical detection of crip-1, amphiregulin and transforming growth factor α in human gastric carcinomas and intestinal metaplasias. *Int. J. Oncol.* 5: 215-223, 1994.
132. Saeki, T., Salomon, D.S., Gullick, W.J., Mandai, K., Yamagami, K., Moriwaki, S., Takashima, S., Nishikawa, Y., and Tahara, E.: Expression of crip-1 in human colorectal adenomas and carcinomas is related to the degree of dysplasia. *Int. J. Oncol.* 5: 445-451, 1994.
133. Yang, Y., Spitzer, E., Kenney, N.L., Zschiesche, W., Li, M., Kromminga, A., Muller, T., Spener, F., Lezius, A., Veerkamp, J.H., Smith, G.H., Salomon, D.D. and Grosse R.: Members of the fatty acid binding protein family are differentiation factors for the mammary gland. *J. Cell Biol.* 127: 1097-1109, 1994.
134. Langton-Webster, B.C., Xuan, J-A., Brink, J.R. and Salomon, D.S.: Development of resistance to cisplatin is associated with decreased expression of the gp185^{c-erb} B-2 protein and alterations in growth properties and responses to therapy in an ovarian tumor cell line. *Cell Growth & Diff.* 5 : 1367-1372, 1994.
135. Salomon, D.S., Normanno, N., Ciardiello, F., Brandt, R., Shoyab, M. and Todaro, G.: The role of amphiregulin in breast cancer. *Breast Cancer Res. Treat.* 33: 103-114, 1995.
136. Kenney, N., Huang, R-P., Johnson, G.R., Wu, J-X., Okamura, D., Matheny, W., Kordon, E., Gullick, W.J., Plwman, G.R., Smith, G.H., Salomon, D.S. and Adamson, E.D.: Detection and location of amphiregulin and crip-1 in the developing mouse mammary gland. *Mol. Reprod. & Develop.* 41: 277-286, 1995
137. Normanno, N., Kim, N., Wen, D., Smith, K., Harris, A.L., Polwman, G., Colletta, G., Ciardiello, F. and Salomon, D.S.: Expression of messenger RNA for amphiregulin, heregulin and crip-1 , three new members of the epidermal growth factor family, in primary human breast carcinomas. *Breast Can. Res. & Treat.* 35: 293-297, 1995.
138. Salomon, D.S., Brandt, R., Ciardiello, F., and Normanno, N.: Epidermal growth factor-related peptides and their receptors in human malignancy. *Crit. Rev. Oncol. & Hematol.* 19: 183-232, 1995 .

139. Normanno, N., Selvam, P., Bianco, C., Damiano, V., De Angelis, E., Grassi, M., Magliulo, G., Tortora, G., Salomon, D.S. and Ciardiello F.: Amphiregulin anti-sense oligodeoxynucleotides inhibit growth and transformation of a human carcinoma cell line. *Int. J. Cancer*. 62:762-766, 1995.
140. Martinez-Lacaci, I., Saceda, M., Plowman, G.D., Johnson, G.R., Normanno, N., Salomon, D.S., and Dickson, R.B.: Regulation of amphiregulin gene expression by 12-O-tetradecanoylphorbol-13-acetate and 17 β -estradiol in human breast cancer cell lines. *Endocrinol.* 136: 3983-3992, 1995.
141. Scala, S., Saeki, T., Lynch, A., Salomon, D.S., Merino, M.J. and Bates, S.E.: Co-expression of TGF α , epidermal growth factor receptor and P-glycoprotein in normal and benign diseased breast tissues. *Diagnostic Molecular Pathology* 4(2): 136-142, 1995.
142. Salomon, D.S., Kannan, S., Kenney, N., Brandt, R., Normanno, N. and Ciardiello, F.: Oncogenes, growth factors, and growth inhibitors in breast cancer. *Curr. Opin. Endocrinology and Diabetes* 2: 500-509, 1995.
143. Saeki, T., Salomon, D.S., Johnson, G.R., Gullick, W.J., Mandai, K., Yamagami, K., Moriwaki, S., Tanada, M., Takashima, S. and Tahara, E.: Association of epidermal growth factor-related peptides and type 1 receptor tyrosine kinase receptors with prognosis of human colorectal carcinomas. *Jpn. J. Clin. Oncol.* 25: 240-249, 1995.
144. Pancino, L., D'Antonio, A., Salvatore, G., Mazza, E., Tortora, G., DeLaurentis, M., DePlacido, S., Giordano, T., Merino, M., Salomon, D.S., Gullick, W.J., Pettinato, G., Bianco, R. and Ciardiello, F.: Differential immunohistochemical detection of transforming growth factor α , amphiregulin and CRIPTO in human normal and malignant breast tissues. *Int. J. Cancer* 65: 51-56, 1996.
145. Kenney, N., Smith, G.H., Maroulakou, I.G., Green, J.H., Muller, W.J., Merlino, G.H., Callahan, R. H., Salomon, D.S. and Dickson, R.B.: Detection of amphiregulin and cripto-1 in mammary tumors from transgenic mice. *Mol. Carcinogenesis*. 15:44-56, 1996.
146. Mincione, G., Bianco, C., Kannan, S., Colletta, G., Ciardiello, F., Sliwkowski, M., Yarden, Y., Normanno, N., Pramaggiore, A., Kim, N. and Salomon, D.S.: Enhanced expression of heregulin in c-erb B-2 and c-Ha-ras transformed mouse and human mammary epithelial cells. *J. Cell. Biochem.* 60: 437-446, 1996.
147. Normanno, N., Bianco, C., Damiano, V., De Angelis, E., Selvam, M.P., Grassi, M., Magliulo, G., Tortora, G., Bianco, A.R., Mendelsohn, J., Salomon, D.S. and Ciardiello, F.: Growth inhibition of human colon carcinoma cells by combinations of anti-EGF-related growth factor antisense oligonucleotides. *Clin. Cancer Res.* 2:601-609, 1996.

MANUSCRIPTS IN PRESS OR SUBMITTED FOR PUBLICATION

1. Saeki, T., Salomon, D.S., Gullick, W.J., Nagasako, K., Futami, S., Mandai, K., Yamagami, K., Moriwaki, S., Nishikawa, Y., Takashima, S. and Tahara, E.: Expression of cripto-1 in nonpolypoid adenomas and carcinomas of the human colon. *GI Cancer* (in press).
2. Kannan, S., De Santis, M., Pramaggiore, A., Lohmeyer, M., Riese, D., Hynes, N.E., Smith, G.H., Seno, M., Bianco, C., Persico, G., Kenney, N.J., Normanno, N., Martinez-Lacaci, I., Ciardiello, F., Stern, D.J., Gullick, W.J. and Salomon, D.S.: Cripto activates the ras/raf/MAP-kinase pathway in mammary epithelial cells. *J. Biol. Chem.* (in press).
3. Kenney, N. J., Smith, G.H., Johnson, M., Lohmeyer, M., Gullick, W.J., Salomon, D.S. and Dickson, R.B.: Cripto-1 activity in the mouse mammary gland: a new candidate that specifically affects ductal progenitor cells. *Developmental Dynamics* (in press).
4. Lohmeyer, M., Sternberg, M., Salomon, D.D. and Gullick, W.J.: Chemical synthesis, structural modelling and biological activity of the epidermal growth factor-like domain of human CRIPTO. *Biochemistry* (in press).
5. Herrington, E.E., Tam, T.G., Salomon, D.S., Johnson, G.R., Gullick, W.J., Kenney, N.J. and Hosick, H.J.: Expression of epidermal growth factor-related proteins in the aged adult mouse mammary gland and their relationship to tumorigenesis. *J. Cell. Physiology*. (in press).

CURRICULUM VITAE

NAME	Isabel Martínez-Lacaci
SOCIAL SECURITY NUMBER	[REDACTED]
DATE OF BIRTH	[REDACTED]
PLACE OF BIRTH	[REDACTED]
WORK PLACE	Laboratory of Tumor Immunology & Biology Rm 5B39; National Cancer Institute; National Institutes of Health 9000 Rockville Pike Bethesda, MD 20892
WORK PHONE NUMBER	(301) 496-9536
FAX NUMBER	(301) 402-8656
E-MAIL ADDRESS	lacacii@ltiblp.nci.nih.gov

EDUCATION

- 1995: Ph.D. degree from Georgetown University, Washington, D.C.
- 1989-1995: Ph. D. candidate at the Department of Cell Biology, School of Medicine, Georgetown University, Washington, D.C.
- 1988: Diploma of LICENCIATE (B.S.) at the Universidad Complutense, Madrid.
Field: Biological Sciences
- 1985-1988: Continuation of college at the Universidad Complutense, Madrid
- 1983-1985: Freshman year of college at the American University, Washington, D.C. ,
and Sophomore year of college at the University of Maryland, College Park, MD.
Field: Biology

WORK EXPERIENCE

- 1995-Present: Postdoctoral fellow at the Tumor Growth Factor Section, LTIB, NCI, NIH, Bethesda, Maryland
- 1990-1995: Predoctoral training at the Vincent T. Lombardi Cancer Research Center and at the Department of Cell Biology, Georgetown University, Washington, D.C. . Mentor: Dr. Robert B. Dickson. Title of dissertation: "Dual Regulation of Amphiregulin Expression in Human Breast Cancer Cell Lines"
- 1989-1995: Teaching assistant in Microscopic Anatomy (Histology) offered by the Department of Cell Biology, School of Medicine, Georgetown University, Washington, D.C.
- Summer 1987, Summer 1988 and 1988-1989: Research project at the Department of Biochemistry, School of Medicine, Georgetown University, Washington, D.C. Mentor: Dr. Vicente Notario.

HONORS AND AWARDS

- 1994: Postdoctoral fellowship for breast cancer research, from the Department of the Army; U.S. Army Medical Research and Development Command
- 1993: Award (second place) in the Predoctoral Division of the VIII Annual Student Research Days competition, Georgetown University, Washington, D.C.

LANGUAGES

- Native speaker of Spanish: spoken, translated, written
- Fluency in English: spoken, translated, written
- Proficiency in Italian: spoken, translated, written

PUBLICATIONS

- Dickson, R.B., Johnson, M.D., Bano, M., Shi, E., Kurebayashi, J., Ziff, B., Martínez-Lacaci, I., Amundadottir, L.T. and Lippman, M.E. (1992). Growth Factors in breast cancer: mitogenesis to transformation. *J. Steroid Biochem, Mol. Biol.* **43**: 69-78
- Normanno, N. Qi, C.-F., Gullik, W.J., Persico, G., Yarden, Y., Wen, D., Plowman, Kenney, N., Johnson, G., Kim, N., Brandt, R., Martínez-Lacaci, I., Dickson, R.B.

and Salomon, D.S. (1993). Expression of amphiregulin, cripto-1, and heregulin α in human breast cancer cells. *Intl. J. Oncol.* **2**: 903-911

- Dickson, R.B., Bano, M., Johnson, M.D., Shi, Y.E., Martínez-Lacaci, I., Amundadottir, L.T., Ziff, B. and Kurebayashi, J. (1994). Steroid regulation of growth factors and protooncogenes in the normal and malignant mammary gland. In *Protooncogenes and Growth Factors in Steroid Hormone Induced Growth and Differentiation*. (Khan, S.A., Stancel, G.M., eds) CRC Press, Boca Ratón, FL, pp. 143-174
- Martínez-Lacaci, I., Saceda, M., Plowman, G.D., Johnson, G.R., Normanno, N., Salomon, D.S. and Dickson R.B. (1995). Estrogen and phorbol esters regulate amphiregulin expression by two separate mechanisms in human breast cancer cell lines. *Endocrinol.* **136**: 3983-3992
- Martínez-Lacaci, I. and Dickson R.B. (1996). Dual regulation of the epidermal growth factor family of growth factors in breast cancer by sex steroids and protein kinase C. *J. Steroid Biochem, Mol. Biol.* **57**: 1-11
- Martínez-Lacaci, I., Johnson, G.R., Salomon, D.S. and Dickson R.B. (1996). Characterization of a novel amphiregulin-related molecule in 12-O-tetradecanoylphorbol-13-acetate treated breast cancer cells. *J. Cell. Physiol.* (In press)
- Kannan, S., DeSantis, M., Pramaggiore, A., Lohmeyer, M., Riese, D., Hynes, N.E, Smith, G.H., Seno, M., Bianco, C., Persico, G., Kenney, N.J., Normanno, N., Martínez-Lacaci, I., Ciardiello, F., Stern, D.J., Gullick, W.J. and Salomon, D.S. (1996). Cripto activates the ras/raf/MAP-kinase pathway in mammary epithelial cells. *J. Biol.Chem.* (In press)

ABSTRACTS

- Martínez-Lacaci, I., Saceda, M., Normanno, N., Salomon, D.S. and Dickson R.B. (1993). Regulation of amphiregulin gene expression by TPA and estradiol in a human breast cancer line, MCF-7. American Association for Cancer Research
- Dickson, R.B., Amundadottir, L.T., Martínez-Lacaci, I., Johnson, M.D., Plowman, G., Saceda, M., Normanno, N., Smith, G., Salomon, D.S. and Merlino, G.T. (1994). Growth factors-sex steroid interactions in breast tumorigenesis. Keystone Symposia in breast and prostate cancer
- Martínez-Lacaci, I., Saceda, M., Johnson, G.R., Salomon, D.S. and Dickson R.B. (1996). Estrogen and phorbol esters signal through enhanced expression of amphiregulin in human breast cancer cells. Keystone Symposia in signal transduction through tyrosine kinases

- De Santis, M., Kannan, K., Martínez-Lacaci, I., Seno, M., Kim, N., Chang, K., Lipsey, K. and Salomon, D.S. (1996). EGF-related growth factors induce development of branching duct-like structures by mammary epithelial cells. XII Annual Meeting on Oncogenes